PD-166793

CAT: 0804-HY-107428-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-107428-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
PD-166793 is a potent, selective, orally active and wide-broad spectrum inhibitor of MMP, exhibiting nanomolar potency against MMP-2, MMP-3 and MMP-13 (IC50=4, 7, and 8 nM, respectively) and micromolar potency vs MMP-1, -7 and -9 (IC50=6.0, 7.2, and 7.9 μM, respectively) . PD-166793 can attenuate left ventricular remodeling and dysfunction in a rat model of progressive heart failure[1][2][3].
CAS Number
[199850-67-4]
UNSPSC
12352005
Target
MMP
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Neuroscience-Neuromodulation
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/pd-166793.html
Purity
99.21
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CC(C)[C@@H](C(O)=O)NS(=O)(C1=CC=C(C2=CC=C(Br)C=C2)C=C1)=O
Molecular Formula
C17H18BrNO4S
Molecular Weight
412.30
References & Citations
[1]O'Brien PM, et, al. Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors. J Med Chem. 2000 Jan 27;43 (2) :156-66.|[2]Kaludercic N, et, al. Inhibiting metalloproteases with PD 166793 in heart failure: impact on cardiac remodeling and beyond. Cardiovasc Ther. Spring 2008;26 (1) :24-37.|[3]Chancey AL, et, al. Effects of matrix metalloproteinase inhibition on ventricular remodeling due to volume overload. Circulation. 2002 Apr 23;105 (16) :1983-8.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
MMP-1; MMP-13; MMP-2; MMP-3; MMP-7; MMP-9

Popular Products